N
CORT icon

Natixis’s Corcept Therapeutics CORT Stock Holding History

Natixis’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.56M Buy
109,905
+109,824
+135,585% +$6.63M 0.04% 308
2026
Q1 		$3.27K Buy
+81
New +$3.03K ﹤0.01% 1047
2021
Q2 		– Sell
-9,300
Closed -$221K – 875
2021
Q1 		$221K Hold
9,300
– – ﹤0.01% 1018
2020
Q4 		$243K Buy
+9,300
New +$196K ﹤0.01% 982
2017
Q4 		– Sell
-11,354
Closed -$219K – 897
2017
Q3 		$219K Buy
+11,354
New +$169K ﹤0.01% 1086
2014
Q2 		– Sell
-11,500
Closed -$50K – 469
2014
Q1 		$50K Buy
+11,500
New +$40.2K ﹤0.01% 491

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Natixis's CORT Position: Q2 2026 in Review

Natixis increased its Corcept Therapeutics (CORT) stake by 135,585% in Q2 2026, buying an estimated $6.63M and bringing the position to 109,905 shares worth $9.56M. The position accounts for 0.04% of the portfolio, ranked #308.

Natixis first reported a position in CORT in Q1 2014 and has held it in 6 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Natixis held 109,905 shares of Corcept Therapeutics worth $9.56M as of Q2 2026.
  • Natixis bought 109,824 Corcept Therapeutics shares in Q2 2026, an estimated $6.63M.
  • Corcept Therapeutics made up 0.04% of Natixis's portfolio in Q2 2026, its #308 holding.
  • Natixis first reported a position in Corcept Therapeutics in Q1 2014 and has held it in 6 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.